Compare Novartis AG (NVS) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs TJX Companies Inc — how do they compare? Novartis AG trades at $143.32 (market cap $268.57B), while TJX Companies Inc trades at $138.76 (market cap $152.62B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and TJX Companies Inc for 97 Days on average.
| NVS | TJX | |
|---|---|---|
Market Cap | $268.57B | $152.62B |
Volume | 1,532,573 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $168.41 |
52-Week Low | $121.80 | $122.84 |
Typical Hold Time | 82 Days | 97 Days |
Enterprise Value | $309.89B | $160.93B |
Dividend Yield | 3.31% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
TJX trades at $138.70, down slightly by 0.07% on the day, with a bullish technical signal from moving averages but overbought RSI readings near 75. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $56.36 billion and $4.86 billion in 2025, respectively, while maintaining a robust ROE of 62.17%.
Wall Street analysts are overwhelmingly bullish, with an 84.9% buy rating and a consensus price target of $174.15, implying 28% upside. Key risks include competitive pressures in off-price retail and potential macroeconomic headwinds affecting consumer spending. The stock's valuation at a P/E of 25.69 appears justified by its earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
